LONDON — The makers of the new heartburn medication “Dancing In A Pool” have been working on a new version for months and they have announced it today.
The drug, which works by lowering blood pressure, is also expected to reduce the risk of heart attacks and strokes.
It’s being developed by New York-based Medi-Cal, the largest health insurance program in the United States and the second largest in the world.
The company said in a statement that the drug was designed to be taken every other day and used to treat a subset of patients.
“This new formulation will be available in all of our pharmacy locations and in many clinical trial sites,” Medi the company said.
“The drug has been approved by the FDA for use in adults and children ages 19 and older with mild to moderate coronary artery disease.”
Medi said the drug is already being tested in some patients who are at higher risk of cardiovascular disease.
It also said the trial was under way.
It said the new version of the drug will be given to approximately 300,000 patients across New York State by mid-2018.
It said it plans to launch the drug at about 60 hospitals.
It also said that the study was under review by the US Food and Drug Administration.
“The trial was conducted in partnership with MediCal and the US Department of Health and Human Services (HHS) and approved by both the FDA and the NIH in 2016,” the company wrote.
“This study is still ongoing and no new data has been submitted for analysis or further comment.
We are in the process of collecting data and will provide a further update when the results are available.”
The drug will cost $12,000 for an eight-week supply.
It is one of a growing number of heartburn medications that include anti-inflammatory drugs such as furosemide.
The new version will be a two-year trial with a $6,000 cap, the company added.